The efficacy and safety of ramipril as monotherapy and in fixed-dose combination with hydrochlorothiazide in the treatment of different groups of hypertensive patients and its effect on cardiovascular prevention

Hypertension is a major health problem in the world. One in every three adults has high blood pressure (BP). The excessive pressure on the artery walls caused by high BP can damage blood vessels, as well as organs in the body. Uncontrolled high BP can lead to different complications. Hypertension is accompanied by cardiovascular risk factors, such as diabetes, previous myocardial infarction or stroke, dyslipidemia, obesity or proven vascular disease, in at least twothirds of all cases. Today’s treatment of hypertension is very challenging, especially in patients with enhanced cardiovascular risk, where a multiple pharmacological approach is often required to achieve an acceptable BP goal. Ramipril is a lipophilic ACE inhibitor suitable for once-daily administration. It effectively reduces peripheral vascular resistance, thus regulating high BP. In combination with hydrochlorothiazide, it produces a synergetic effect, which increases the efficacy and safety of both drugs. Ramipril has been studied in numerous clinical studies. Also the efficacy and safety of Krka’s ramipril (Ampril®) have been studied in several clinical and post-authorisation safety and efficacy studies. Krka’s ramipril is offered in a variety of dosage forms, strengths and fixed-dose combination